Schering Corporation

Other

Merck Sharp + Dohme Corp.

Michael D Green

Tiruvettipuram K Thiruvengadam

Anantha R Sudhakar

George G Wu

Minzhang Chen

Tao Wang

Mingsheng Huang

Chou-Hong Tann

John S Chiu

Cesar Colon

Daw-long Albert Kwok

Ngiap Kie Lim

Fucheng Zhang

Gregory Wayne Driskell

Jeonghan Park

Ilia A Zavialov

George S Wong

Hoa N Nguyen

Vilas Hareshwar Dahanukar

Juergen Weber

Ingyu Jeon

Cecilia A Orr

Daw-Iong Albert Kwok

Tetsuo Iwama

Ngiap-Kie Lim

In some embodiments, a directional surface marking may provide directional messaging to users based on their direction of travel on a base surface, such as a roadway, walkway, or interior flooring, as non-limiting examples. In some aspects, the directional messaging may comprise different colors, text, or symbols, wherein a user may view different directional messaging on a directional surface marking dependent on direction of travel. In some embodiments, directional surface markings may comprise a profile layer, wherein the profile layer may comprise a plurality of profiles, which may provide a topography that allows for directional messaging utilizing surface colors on the topography.

Directional surface marking safety and guidance devices and systems

In some embodiments, a directional surface marking may provide directional messaging to users based on their direction of travel on a base surface, such as a roadway, walkway, or interior flooring, as non-limiting examples. In some aspects, the directional messaging may comprise different colors, text, or symbols, wherein a user may view different directional messaging on a directional surface marking dependent on direction of travel. In some embodiments, directional surface markings may comprise a profile layer, wherein the profile layer may comprise a plurality of profiles, which may allow for an application of directional messaging.

This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide route, and the chiral carbamate ester route. The compounds produced thereby are useful as thrombin receptor antagonists. The chemistry disclosed herein is exemplified in the following synthesis sequence: 

Exo-selective synthesis of himbacine analogs

In one embodiment, the present application relates to a process of making a compound of formula I: and to certain intermediate compounds that are made within the process of making the compound of formula I.

Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof

Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl

The disclosed embodiments of exercise garments includes a torso portion adapted to substantially cover the torso of a user and one or more flaps. Each flap is secured substantially to a side of the torso portion. The exercise garment also includes at least one fastener adapted to selectively secure the pair of flaps across at least a portion of an abdominal region of the user. The fasteners may include a hook-and-loop arrangement (such as Velcro7), buttons or snaps. The illustrated embodiment includes a pair of flaps, which may overlap over the abdominal region when both flaps are secured. The fasteners may be adapted to provide adjustable positioning of the flaps. The adjustable positioning includes variable placement of the flaps relative to the abdominal region. The torso portion may also include a corset arrangement extending from a top portion of the torso portion downward through at least a portion of the abdominal region.

Exercise suit

In one embodiment, the present application relates to a process of making a compound of formula I:and to certain intermediate compounds that are made within the process of making the compound of formula I.

There is disclosed a novel formylating agent, 2-formylmercaptobenzothiazole.

2-formylmercaptobenzothiazole

An improved process for converting gentamicin B to isepamicin comprising forming 3,6'-di-N-formylgentamicin B, acylating the 1-amino group with an N-protected (S)-isoserine compound and removing all the blocking groups under conditions which result in high yields of isepamicin. A novel formylating agent, 2-formylmercaptobenzothiazole, and intermediate compounds are also disclosed.

Process for preparing isepamicin

Growing community of inventors

Willingboro, NJ, United States of America

Michael D Green